Psychiatric medications, science, marketing, psychiatry in general, and occasionally clinical psychology. Questioning the role of key opinion leaders and the use of "science" to promote commercial ends rather than the needs of people with mental health concerns.
Friday, November 17, 2006
Atypical Antipsychotic Results (Guess)
Another study (White et al in the latest Schizophrenia Research) comparing first and second generation antipsychotics, this time in elderly patients with severe (poor outcome) schizophrenia, found that there was no difference in their ability to impact positive or negative symptoms over time. This goes hand in hand with other trials (like this and this) that have failed to differentiate the two classes in terms of efficacy. Yes, I am aware that older antipsychotics induce tardive dyskinesia and other horrendous effects, but the new meds are not exactly a walk in the park when it comes to safety!
No comments:
Post a Comment